Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385708915> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W4385708915 abstract "In recent years, novel agents have become available to treat relapsed/refractory diffuse large B-cell lymphoma (DLBCL); the impact of such agents on treatment costs has not been formally studied. We present results from 2 independent, retrospective, real-world cohort analyses to determine the cost of disease progression after first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).Analyses were conducted using the IQVIA PharMetricsⓇ Plus claims database and the Surveillance, Epidemiology, and End Results registry-Medicare-linked database (SEER-Medicare) and included patients ≥18 years and ≥66 years, respectively. No progression was defined as no second-line therapy for ≥2 years after the end of first-line R-CHOP and treated progression as initiating a second-line therapy within 2 years following the end of first-line R-CHOP. Analyses were adjusted for baseline covariates, and per-patient-per-month (PPPM) costs were compared between progressors and nonprogressors.The IQVIA PharMetrics Plus analysis (January 1, 2010-June 30, 2018) included 871 patients (nonprogressors, n = 725; progressors, n = 146), including 10 patients who received chimeric antigen receptor T-cell therapy (CAR-T). Treated progression was associated with significantly higher adjusted PPPM costs than no progression ($10,554 vs. $1561, P < .001). The SEER-Medicare analysis (January 1, 2010-December 31, 2017) included 4099 patients (nonprogressors, n = 3389; progressors, n = 710), including 12 patients receiving CAR-T. Treated progression was associated with significantly higher adjusted PPPM costs than no progression ($10,928 vs. $2902, P < .001).Treated progression of DLBCL increases adjusted PPPM costs by over $8000 compared with no progression." @default.
- W4385708915 created "2023-08-10" @default.
- W4385708915 creator A5030851085 @default.
- W4385708915 creator A5032057859 @default.
- W4385708915 creator A5047960113 @default.
- W4385708915 creator A5049461398 @default.
- W4385708915 creator A5052585719 @default.
- W4385708915 creator A5055115466 @default.
- W4385708915 creator A5061916244 @default.
- W4385708915 creator A5065362776 @default.
- W4385708915 date "2023-08-01" @default.
- W4385708915 modified "2023-10-17" @default.
- W4385708915 title "Cost of Disease Progression in Diffuse Large B-Cell Lymphoma After Frontline Treatment With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone" @default.
- W4385708915 cites W2058015212 @default.
- W4385708915 cites W2310716991 @default.
- W4385708915 cites W2314750237 @default.
- W4385708915 cites W2754056099 @default.
- W4385708915 cites W2810179171 @default.
- W4385708915 cites W2920959584 @default.
- W4385708915 cites W2980636884 @default.
- W4385708915 cites W3134205746 @default.
- W4385708915 cites W3199609266 @default.
- W4385708915 cites W4234961057 @default.
- W4385708915 doi "https://doi.org/10.1016/j.clml.2023.08.005" @default.
- W4385708915 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37704514" @default.
- W4385708915 hasPublicationYear "2023" @default.
- W4385708915 type Work @default.
- W4385708915 citedByCount "0" @default.
- W4385708915 crossrefType "journal-article" @default.
- W4385708915 hasAuthorship W4385708915A5030851085 @default.
- W4385708915 hasAuthorship W4385708915A5032057859 @default.
- W4385708915 hasAuthorship W4385708915A5047960113 @default.
- W4385708915 hasAuthorship W4385708915A5049461398 @default.
- W4385708915 hasAuthorship W4385708915A5052585719 @default.
- W4385708915 hasAuthorship W4385708915A5055115466 @default.
- W4385708915 hasAuthorship W4385708915A5061916244 @default.
- W4385708915 hasAuthorship W4385708915A5065362776 @default.
- W4385708915 hasBestOaLocation W43857089151 @default.
- W4385708915 hasConcept C126322002 @default.
- W4385708915 hasConcept C141071460 @default.
- W4385708915 hasConcept C143998085 @default.
- W4385708915 hasConcept C2776694085 @default.
- W4385708915 hasConcept C2776755627 @default.
- W4385708915 hasConcept C2778559949 @default.
- W4385708915 hasConcept C2778720950 @default.
- W4385708915 hasConcept C2779338263 @default.
- W4385708915 hasConcept C2779429289 @default.
- W4385708915 hasConcept C2779725641 @default.
- W4385708915 hasConcept C2780653079 @default.
- W4385708915 hasConcept C71924100 @default.
- W4385708915 hasConceptScore W4385708915C126322002 @default.
- W4385708915 hasConceptScore W4385708915C141071460 @default.
- W4385708915 hasConceptScore W4385708915C143998085 @default.
- W4385708915 hasConceptScore W4385708915C2776694085 @default.
- W4385708915 hasConceptScore W4385708915C2776755627 @default.
- W4385708915 hasConceptScore W4385708915C2778559949 @default.
- W4385708915 hasConceptScore W4385708915C2778720950 @default.
- W4385708915 hasConceptScore W4385708915C2779338263 @default.
- W4385708915 hasConceptScore W4385708915C2779429289 @default.
- W4385708915 hasConceptScore W4385708915C2779725641 @default.
- W4385708915 hasConceptScore W4385708915C2780653079 @default.
- W4385708915 hasConceptScore W4385708915C71924100 @default.
- W4385708915 hasFunder F4320307779 @default.
- W4385708915 hasLocation W43857089151 @default.
- W4385708915 hasLocation W43857089152 @default.
- W4385708915 hasOpenAccess W4385708915 @default.
- W4385708915 hasPrimaryLocation W43857089151 @default.
- W4385708915 hasRelatedWork W1896861650 @default.
- W4385708915 hasRelatedWork W1921119956 @default.
- W4385708915 hasRelatedWork W1986487042 @default.
- W4385708915 hasRelatedWork W2017046780 @default.
- W4385708915 hasRelatedWork W2031021461 @default.
- W4385708915 hasRelatedWork W2044362603 @default.
- W4385708915 hasRelatedWork W2047206303 @default.
- W4385708915 hasRelatedWork W2087824134 @default.
- W4385708915 hasRelatedWork W2138201596 @default.
- W4385708915 hasRelatedWork W2143831053 @default.
- W4385708915 isParatext "false" @default.
- W4385708915 isRetracted "false" @default.
- W4385708915 workType "article" @default.